Evidence map›Paper›PMID 30165047›Full record

ArticleGastroenterology2018

microRNA 193a-5p Regulates Levels of Nucleolar- and Spindle-Associated Protein 1 to Suppress Hepatocarcinogenesis.

Sanchari Roy, Guido J Hooiveld, Marco Seehawer, Stefano Caruso, Florian Heinzmann, Anne T Schneider, Anna K Frank, David Vargas Cardenas, Roland Sonntag, Mark Luedde and 15 more

Open access · greenAbstract read
In one paragraph

Article in Gastroenterology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
60citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

60 citing papers in PubMed, 1 synthesis or guideline pooled it, 82 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. The role and therapeutic value of NUSAP1 in human cancers.Journal of translational medicine · 2025
    Review
  5. Article
  6. Review
  7. Gene targets with therapeutic potential in hepatocellular carcinoma.World journal of gastrointestinal oncology · 2024
    Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Cell cycle (Georgetown, Tex.) · 2022
    Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 10 institutions in 5 countries.

Sanchari RoyDivision of Gastroenterology, Hepatology and Hepatobiliary Oncology, Aachen Germany; Department of Medicine III, University Hospital RWTH Aachen, Aachen Germany.
Guido J HooiveldNutrition, Metabolism & Genomics Group, Division of Human Nutrition, Wageningen University, Wageningen, Netherlands.
Marco SeehawerDepartment of Internal Medicine VIII, University Hospital Tübingen, Tübingen, Germany; Department of Physiology I, Institute of Physiology, Eberhard Karls University Tübingen, Tübingen, Germany.
Stefano CarusoInserm UMR-1162, Functional Genomics of Solid Tumors, University Paris Descartes, University University Paris Diderot, University Paris 13, Labex Immuno-Oncology, Paris, France.
Florian HeinzmannDepartment of Internal Medicine VIII, University Hospital Tübingen, Tübingen, Germany; Department of Physiology I, Institute of Physiology, Eberhard Karls University Tübingen, Tübingen, Germany.
Anne T SchneiderDivision of Gastroenterology, Hepatology and Hepatobiliary Oncology, Aachen Germany.
Anna K FrankDepartment of Medicine III, University Hospital RWTH Aachen, Aachen Germany.
David Vargas CardenasDivision of Gastroenterology, Hepatology and Hepatobiliary Oncology, Aachen Germany.
Roland SonntagDepartment of Medicine III, University Hospital RWTH Aachen, Aachen Germany.
Mark LueddeDepartment of Cardiology, University Hospital Kiel, Kiel, Germany.
Christian TrautweinDepartment of Medicine III, University Hospital RWTH Aachen, Aachen Germany.
Ilan SteinDepartment of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Eli PikarskyDepartment of Pathology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.
Sven LoosenDepartment of Medicine III, University Hospital RWTH Aachen, Aachen Germany.
Frank TackeDepartment of Medicine III, University Hospital RWTH Aachen, Aachen Germany.
Marc RingelhanTechnische Universität München, München, Germany.
Seda Kilinc AvsarogluDepartment of Cell and Tissue Biology, University of California, San Francisco, California.
Andrei GogaDepartment of Cell and Tissue Biology, University of California, San Francisco, California.
Marie-Annick BuendiaInserm Unit U1193, University Paris-Sud, Paul Brousse Hospital, Villejuif, France.
Mihael VucurDivision of Gastroenterology, Hepatology and Hepatobiliary Oncology, Aachen Germany.
Mathias HeikenwalderDivision of Chronic Inflammation and Cancer, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Jessica Zucman-RossiInserm UMR-1162, Functional Genomics of Solid Tumors, University Paris Descartes, University University Paris Diderot, University Paris 13, Labex Immuno-Oncology, Paris, France.
Lars ZenderDepartment of Internal Medicine VIII, University Hospital Tübingen, Tübingen, Germany; Department of Physiology I, Institute of Physiology, Eberhard Karls University Tübingen, Tübingen, Germany; Translational Gastrointestinal Oncology Group, German Consortium for Translational Cancer Research (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany.
Christoph RoderburgDepartment of Medicine III, University Hospital RWTH Aachen, Aachen Germany.
Tom LueddeDivision of Gastroenterology, Hepatology and Hepatobiliary Oncology, Aachen Germany; Department of Medicine III, University Hospital RWTH Aachen, Aachen Germany. Electronic address: tluedde@ukaachen.de.
RWTH Aachen University · DEInserm · FRGerman Cancer Research Center · DEHadassah Medical Center · ILUniversitätsklinikum Aachen · DEUniversity Children's Hospital Tübingen · DEUniversity of California, San Francisco · USChristian-Albrechts-Universität zu Kiel · DETechnical University of Munich · DEWageningen University & Research · NL

Funding

Transcellular epigenetic regulation by ex-small RNA in C. elegantU19CA179512 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI BLELLOCH, ROBERT · 2013 to 2017
$7.4M
In Vivo Metabolic Catastrophe Is Induced By Acute Oncogene Inhibition (PQ #22)R01CA170447 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GOGA, ANDREI · 2012 to 2015
$2.4M
NCI NIH HHS R01 CA170447NCI NIH HHS U19 CA179512
6 · The paper itself

Abstract

BACKGROUND &

aimsWe performed an integrated analysis to identify microRNAs (miRNAs) and messenger RNAs (mRNAs) with altered expression in liver tumors from 3 mouse models of hepatocellular carcinoma (HCC) and human tumor tissues.

methodsWe analyzed miRNA and mRNA expression profiles of liver tissues from mice with diethylnitrosamine-induced hepatocarcinogenesis, conditional expression of lymphotoxin alpha and lymphotoxin beta, or inducible expression of a Myc transgene (Tet-O-Myc mice), as well as male C57BL/6 mice (controls). miRNA mimics were expressed and miRNAs and mRNAs were knocked down in human (Huh7, Hep3B, JHH2) hepatoma cell lines; cells were analyzed for viability, proliferation, apoptosis, migration, and invasion. Cells were grown as xenograft tumors in nude mice and analyzed. We combined in silico target gene prediction with mRNA profiles from all 3 mouse models. We quantified miRNA levels in 146 fresh-frozen tissues from patients (125 HCCs, 17 matched nontumor tissues, and 4 liver samples from patients without cancer) and published human data sets and tested correlations with patient survival times using Kaplan-Meier curves and the log-rank test. Levels of NUSAP1 mRNA were quantified in 237 HCCs and 5 nontumor liver samples using the TaqMan assay.

resultsLevels of the miRNA 193a-5p (MIR193A-5p) were reduced in liver tumors from all 3 mouse tumor models and in human HCC samples, compared with nontumor liver tissues. Expression of a MIR193A-5p mimic in hepatoma cells reduced proliferation, survival, migration, and invasion and their growth as xenograft tumors in nude mice. We found nucleolar and spindle-associated protein 1 (NUSAP1) to be a target of MIR193A-5p; HCC cells and tissues with low levels of MIR193A-5p had increased expression of NUSAP1. Increased levels of NUSAP1 in HCC samples correlated with shorter survival times of patients. Knockdown of NUSAP1 in Huh7 cells reduced proliferation, survival, migration, and growth as xenograft tumors in nude mice. Hydrodynamic tail-vein injections of a small hairpin RNA against NUSAP1 reduced growth of Akt1-Myc-induced tumors in mice.

conclusionsMIR193A-5p appears to prevent liver tumorigenesis by reducing levels of NUSAP1. Levels of MIR193A-5p are reduced in mouse and human HCC cells and tissues, leading to increased levels of NUSAP1, associated with shorter survival times of patients. Integrated analyses of miRNAs and mRNAs in tumors from mouse models can lead to identification of therapeutic targets in humans. The currently reported miRNA and mRNA profiling data have been submitted to the Gene Expression Omnibus (super-series accession number GSE102418).

Indexed as

ApoptosisAnimalsCarcinogenesisCarcinoma, HepatocellularCell Cycle ProteinsCell Line, TumorCell ProliferationGene Expression Regulation, NeoplasticHumansLiverLiver NeoplasmsMaleMiceMice, Inbred C57BLMice, NudeMicroRNAsCell Cycle ProteinsMicroRNAsMicrotubule-Associated ProteinsMIRN193 microRNA, mouseNuclear ProteinsNuSAP protein, mouseRNA, MessengerRNA, Small InterferingSPAG5 protein, humanGene RegulationLiver CancerSystems BiologyTranslation

Identifiers

PMID30165047
PMCPMC6279541
OpenAlexW2889119877

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.